Trial Profile
A retrospective case series to assess objective response and tolerability of Cabozantinib in Refractory Adrenocortical Carcinoma
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 24 Apr 2018
Price :
$35
*
At a glance
- Drugs Cabozantinib (Primary)
- Indications Adrenocortical carcinoma
- Focus Therapeutic Use
- 24 Apr 2018 New trial record
- 20 Mar 2018 Results presented at The 100th Annual Meeting of the Endocrine Society